dataesr/scientific-paragraphs-categorization huggingface dataset:
For patients with pN1 prostate cancer who have undetectable PSA after RP with extended PLND, a number of factors can help inform the decision to offer aRT, including pathological tumour status (pT), pathological margin involvement, ISUP grade group, and the number of involved lymph nodes  [6]. For pN1 patients, cancer mortality seems to rise drastically when three or more lymph nodes are positive (pathological)  [75] [76] [77] [78] , and it is in such a high-risk setting that aRT might confer the most benefit. In an observational study of the National Cancer Database, among >8000 patients who were pN1 after RP, aRT in addition to ADT was associated with a statistically significant improvement in OS, which was particularly pronounced among patients with adverse pathological features (!pT3b disease, GS !9, more than three positive lymph nodes, or positive surgical margins)  [79].
For patients with the same characteristics but PSA-DT 12 mo and/or ISUP 4-5 disease, 67% of panellists voted in favour of immediate systemic therapy. For patients with a limited number of positive lymph nodes in the pelvis on PSMA PET after prior RT of the prostate alone, there was a consensus for locoregional treatment plus systemic therapy. In summary, PSMA PET has become a preferred imaging modality for patients with PSA persistence and BCR, but the management of these common and heterogeneous situations remains challenging. Large trials of specific populations or at least subgroups with prognostic stratification factors are needed. Several relevant trials are on-going (ie, INDICATE NCT04423211 and PRESTO NCT04115007) and will hopefully lead to improved understanding. Many patients with BCR may not need treatment; thus, it will be important to obtain robust data to build on when making treatment decisions.
Support and role of the sponsor: We gratefully acknowledge the following organisations for providing financial support for the APCCC 2022: The City of Lugano and Movember Foundation. Ros Eeles is supported by a National Institute of Health Research grant to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. We also acknowledge sponsorship from several for-profit organisations for APCCC 2022, including Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer Health Care, Debiopharm, MSD, Janssen Oncology, Myovant Sciences, Orion Pharma, Pfizer Oncology, Roche, Telix Innovations SA, Ferring Pharmaceuticals, Lantheus, and Tolmar. These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication.
Funding/ Support and role of the sponsor: We gratefully acknowledge the following organisations for providing financial support for the APCCC 2022: The City of Lugano and Movember Foundation. Ros Eeles is supported by a National Institute of Health Research grant to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. We also acknowledge sponsorship from several for-profit organisations for APCCC 2022, including Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer Health Care, Debiopharm, MSD, Janssen Oncology, Myovant Sciences, Orion Pharma, Pfizer Oncology, Roche, Telix Innovations SA, Ferring Pharmaceuticals, Lantheus, and Tolmar. These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication.
Search Methods A search of PubMed was first performed in January 2022 using the keywords (''Primary Pterygium'' OR ''Primary Pterygium Recurrence'') AND (''Conjunctival Autograft'' OR ''Limbal Conjunctival Autograft'' OR ''Amniotic Membrane''); this retrieved 111 results  (58 CAT, 20 LCA, 27 AMG and 6 combined techniques). All studies published between 1993 and 2022 with at least 3 months of follow-up were eligible, but only those reporting real-life retrospective data and that were not RCTs or subgroup analyses of RCTs were selected (Fig. 1 ). Two reviewers independently assessed the included studies for potential sources of bias. One author independently extracted data from the included studies regarding year and country of publication, study population, time of follow-up, surgical technique, fixation technique, use of mitomycin C (MMC), post-operative treatment, definition of recurrence and mean recurrence rate.
Acknowledgments The authors are grateful to  J. Konstantinovic  ( HIPS, Saarbrücken ) for assisting with HRMS. K. R. thanks  J. Wolf  and  K. V. Sander  for excellent technical assistance. K. R. receives support from the  German Center for Infection Research (DZIF ,  TTU 09. 710  and  09. 719 ). A. T. acknowledges the  European Research Council  ( ERC Starting Grant , Sweetbullets) and  DZIF  ( TTU 09. 718 ). A. I. thanks the  French National Research Agency  [ ANR-17-CE11-0048 ] project ' Glycomime'for support and further acknowledges Glyco@Alps  ( ANR-15-IDEX-0002 ) and  Labex Arcane/CBH-EUR - GS  ( ANR-17-EURE-0003 ). This research was also funded by the  EU   Horizon 2020 Research and Innovation Program  under the  Marie Skłodowska-Curie grant agreement synBIOcarb  (No. 814029 ). This publication is partially based upon work from  COST Action   CA18103  (INNOGLY), supported by  COST (European Coorperation in Science and Technology).
Unlocking the gateway: exploring cell entry and receptor interactions Since 2016, researchers have dedicated their attention to understanding the molecular mechanisms and cellular signaling pathways involved in the pathogenicity of ZIKV. A comprehensive database, presented in Table  1 , has been compiled to identify the human cells susceptible the ZIKV infection. ZIKV exhibits a broad range of tropism, targeting various cell types including the brain, placenta, skin, testis, kidneys, and retina  [55]. The entry of ZIKV into human primary trophoblasts is facilitated by phosphatidylserine receptors, specifically those belonging to the TIM (TIM1, TIM4) and TAM (Axl, Tyro3)  [56, 57]. Given that mosquito bites remain the predominant mode of transmission of ZIKV, cells residing in the epidermis and dermis have been identified as the primary cellular targets for ZIKV infection.
We created a variable for alcohol use using data generated from the AUDIT-C instrument, a 3-item questionnaire designed to screen for hazardous drinking or those who have active alcohol use disorders. We classified participants as non-drinkers, no misuse, or hazardous drinkers/alcohol use disorder. Cannabis use in the past 12 months was dichotomized as non-user versus user. Other drug use in the past 12 months was collected via a single question on use of "other drugs to feel better or get high". We created a composite variable identifying those who used drugs commonly associated with Chemsex by aggregating reported use of poppers and/or cocaine and/or amphetamines and/or GHB/GBL and/or synthetic cathinones at home or someone else's home. Two categorical variables were then created for both general drug use and Chemsex, coded as non-other drug user, users of a specific drug (e.
Acknowledgements We would like to acknowledge  Alain Volny-Anne (European AIDS Treatment Group)  who reviewed the content of the battery of PRO measures and colleagues at  AIDeS  who are part of the  QuAliV Steering Committee. We also thank  Eugenie Destandau  who provided input on the QuAliV study's communication strategy. We acknowledge the contribution of members of the  IT department  who developed the APREGE ® 2. 0 module for the collection.
Background Hyperglycaemia is common in critically ill patients, but blood glucose and insulin management may differ widely among intensive care units (ICUs). We aimed to describe insulin use practices and the resulting glycaemic control in French ICUs. We conducted a multicentre 1-day observational study on November 23, 2021, in 69 French ICUs. Adult patients hospitalized for an acute organ failure, severe infection or post-operative care were included. Data were recorded from midnight to 11:59 p. m. the day of the study by 4-h periods.
Data were recorded from midnight to 11:59 p. m. the day of the study by 4-h periods. The study was approved by the Ethic Committee of the French Intensive Care Society on 8 th August 2021 (CE SRLF 21-67). Patients, or their family, were informed of the study by the Welcome Booklet of each ICU or a dedicated information letter, and their right to refuse participation and how to do so was clearly stated. The study complied with French law and health data protection regulations. Variables collected included patients' baseline clinical characteristics, reason for ICU admission, chronic illnesses, chronic medications, insulin type and dose administered on the study day, dietary intakes, sequential organ failure assessment (SOFA) score on the study day  [18] , number of blood glucose tests performed on the study day, and minimal and maximal values of blood glucose recorded during each 4-h time slot.
Acknowledgements The authors wish to thank all the investigators :  Laurent Argaud  ( CHU de Lyon ),  Pierre Asfar  ( CHU d' Angers ),  Florent Beaumale  ( CHU d' Angers ),  Sébastien Beague  ( CH de Dunkerque ),  Sandrine Bedon Carte  ( CH de Périgueux ),  Mathieu Beis  ( CH d'Epinal ),  Guillaume Besch  ( CHU de Besançon ),  Vlad Botoc  ( CH de Saint-Malo ),  Karama Bouchaala  ( CH de Béthune ),  Anne-Laure Bouilland  ( CHU Henri Mondor ),  Cédric Bruel  ( Hôpital Paris Saint-Joseph ),  Paul Delval  ( Hôpital Paris Saint-Joseph ),  Charles Cerf  ( Hôpital Foch ),  Mathilde Neuville  (Hôpital.
Also, no clouds (i. e. , liquid water) are present in the air, although they are known to have a non-negligible impact on the radiative forcing. Moreover, the model is only 1D vertical and works well only for a tropical column where vertical fluxes dominate. Finally, a reason for getting different results could be the possible lack of validity of the MEP hypothesis. That said, obtaining the same order of magnitude of precipitation as in the IPSL-CM6A-LR model is surprising, which means 1. 2 m. yr -1 compared to 1. 4 m. yr -1. We note that when extracting data from the IPSL-CM6A-LR model, we could have chosen a different latitude to take the mean or focused only on oceans. It would have changed the obtained precipitation but not the order of magnitude. Here we chose to take the mean precipitations between ±23 • because it is coherent with the vertical temperature and gases columns took from  McClatchey (1972).
ACKNOWLEDGMENTS We thank  Pr B. Lina  for providing the SARS-CoV-2 BA. 2, BA. 5, and XBB strains. We thank  Rayane Amaral  and  Camille Placidi-Italia  for the technical help regarding the molecular biology experiments and the cell culture. We thank  Dr Cecile Baronti  for her help and expertise regarding BSL3 experiments at UVE. We thank the staff of the  National Reference Center  for technical help, the team of the  Mutualized Platform of Microbiology (P2M) at Institut Pasteur  for help with sequencing and bioinformaticians of the  Bioinformatics Hub at Institut  for help with sequence analysis. We are indebted to  Dr. H. Mouquet  ( Institut Pasteur, Paris, France ) for providing the Bebtelovimab/LY-Cov1404 antibody. We thank the public and private laboratories for providing specimens and aknowledge the EMERGEN genomic surveillance consortium.
We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID and GenBank. This work was performed in the framework of the Preclinical Study Group of the French agency for emerging infectious diseases (ANRS-MIE). It was supported by the  ANRS-MIE  ( BIOVAR  and  PRI  projects of the  EMERGEN research program ) and by the  European Commission (European Virus Archive Global  project ( EVA GLOBAL , grant agreement No  871029 ) of the  Horizon 2020 research and innovation program ). The  SVDW  and  ESL laboratories  acknowledge funding from the  European Commission  ( RECOVER project , grant agreement No  101003589 ) of the  Horizon 2020 research and innovation program  and by the  French Government 's  Investissement d'Avenir program ,  Laboratoire d'Excellence  '' Integrative Biology of Emerging Infectious Diseases' ' (grant n  ANR-10-LABX-62-IBEID ).
The  SVDW  lab acknowledges funding from  Santepublique France  (the  French national public health agency) , the '' Enhancing Whole Genome Sequencing (WGS)  and/or  Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures  and capacities to respond to the  COVID-19 pandemic in the European Union and European Economic Area '' Grant Agreement  ECDC/HERA/2021/007 ECD. 12221 , and the  Caisse nationale d'assurance maladie (Cnam) , the national health insurance funds. The  ESL laboratory  acknowledges funding from the  INCEPTION program (Investissements d'Avenir  grant  ANR-16-CONV-0005 ), the  NIH   PICREID program  (Award Number  U01AI151758 ).
Introduction. Cat scratch disease (CSD) is the most common cause of bacterial infectious lymphadenopathy, especially in children, but its diagnosis still remains challenging. Serological assays are widely applied due to their simplicity and the non-invasive sampling. However, these techniques present several limitations, including not well-defned antigen preparation, assay conditions and cutof titers, severe cross-reactions with other species and organisms, and the notably ranging seroprevalence in the normal population. Te objective of this study is to review the literature in order to determine the best diagnostic procedure for the diagnosis of CSD. Methods. Databases including PubMed, Medline, Google Scholar, and Google were searched to determine the best diagnostic procedure for the diagnosis of CSD.
Additionally, the nature of the vector itself can have a direct impact on its accumulation Figure 1. Crystal structure of PSMA in its noncovalent homodimeric form; PDB: 1Z8L (left)  [16]  and schematic representation of the PSMA homodimer. The full-length monomeric protein (~100 kDa molecular weight) includes a transmembrane region (24 amino acids), a short N-terminal cytoplasmic sequence (19 AA) which contains the capromab binding site, and a large, highly glycosylated extracellular domain (707 AA, 9 predicted N-glycosylation sites). The extracellular domain contains two domains of unknown function (106 and 123 AA) separated by proline-and glycine-rich regions (27 and 24 AA) and an exopeptidase-like catalytic domain containing the PSMA ligands recognition site. Additionally, a helical dimerization domain is located at the C-terminal end, with no known functions.
Therefore, subsequent clinical trials have been conducted to evaluate the efficacy and safety of ARPI + radium-223 combination therapy, among which the EORTC 1333/PEACE 3 trial with enzalutamide (NCT02194842) and the ERA 223 trial with abiraterone acetate (NCT02043678). The ERA 223 trial was terminated prematurely due to excessive rate of skeletal-related events  [50]. This highlighted the importance of using bone-protecting agents (BPAs) in association with radium-223, as in both the intervention and control arms, frequency of fractures was lower when patients received BPAs with their assigned therapy. Since then, an amendment was made in PEACE 3 to compel the use of a BPA such as the anti-receptor activator of nuclear factor-kappa B ligand (RANK-L) antibody denosumab. To date, the enrollment of this study is still ongoing.
All patients had two PET/CT: one [ 68 Ga]Ga-PSMA-11 PET imaging to confirm the high PSMA expression and one [ 18 F]FDG PET imaging to exclude patients with PSMA-negative FDG-positive lesions. A total of 43 patients were screened, and 30 patients were included. Half of the patients had a PSA response (57%) and 70% had a PSA decline of at least 30%. Among the 17 patients with measurable disease, the objective response rate was 82% (n = 14). In a randomized phase II clinical trial (TheraP, NCT03392428), [ 177 Lu]Lu-PSMA-617 was compared to cabazitaxel in patients previously treated with docetaxel and at least one ARPI  [52]. As in the previous phase II trial, [ 68 Ga]Ga-PSMA-11 and [ 18 F]FDG PET/CT were performed before randomization with the same inclusion criteria. [ 177 Lu]Lu-PSMA-617 was given at the dosage of 6.
• To enhance the radiation-induced immunologic shift and increase the efficacy of immunotherapy. The emergence of immune checkpoint inhibitors has changed the landscape of treatment in many solid cancers  [60]. However, the low immunogenicity of prostate cancers limits the benefit of treatments such as programmed death receptor 1 (PD-1) inhibitors. A phase 1b, single arm study (NCT03805594) investigated the potential immunogenic priming effect of a single dose of [ 177 Lu]Lu-PSMA-617 in chemotherapy-naïve patients with mCRPC, subsequently treated with pembrolizumab (anti-PD1)  [61]. Among the 18 patients enrolled, the median radiological PFS was 6. 5 months (95% CI 2. 5-9. 8). Interestingly, somatic genomic data showed that all patients carried low tumor mutational burden. A case report also mentions two patients treated with 177 Lu-labeled PSMA concomitantly with pembrolizumab and sequentially with Olaparib (anti-PARP oral therapy), respectively  [62].
The first patient showed PSA stabilization after three cycles, and the second patient achieved radiological and biochemical response. More recently, the PRINCE phase I clinical trial (NCT03658447) recruited 37 mCRPC patients who received up to six cycles of [ 177 Lu]Lu-PSMA-617 in conjunction with pembrolizumab for up to 2 years  [63]. Median radiological PFS, PSA-PFS and OS were 11. 2 months (95% CI 5. 1-14. 1), 8. 2 months (95% CI 5. 1-11. 2) and 17. 8 months (95% CI 13. 4-not estimable). No new safety concerns were observed, encouraging further evaluation of this type of combination. Notably, combination therapy associating PSMA RLT and cytotoxic chemotherapy within a same protocol are, to our knowledge, not yet studied, as is the case with DOTATATE in neuroendocrine tumors (e. g. , CAAA601A42101 clinical trial, NCT05142696).
Interestingly, a 227 Th-labeled PSMA-specific monoclonal antibody (Th-PSMA-TTC, BAY2315497) bearing a 3,2-HOPO chelator moiety is currently in phase 1 clinical trial to evaluate its safety, tolerability, pharmacokinetics and antitumor activity, alone or in combination with darolutamide, in patients with mCRPC (NCT03724747)  [101] [102] [103]. Analogs of previously described vectors, such as bivalent molecules co-targeting albumin, displaying increased tumor uptake because of their enhanced blood circulation properties, were recently evaluated in first-in-human studies. [ 177 Lu]Lu-PSMA-ALB-56 was injected in 10 patients with mCRPC (3360 ± 393 MBq) and showed normalized absorbed doses up to 2. 3-fold higher in tumor lesions (6. 64 ± 6. 92 Gy/GBq) than conventional 177 Lu-labeled PSMA ligands.
Doses were similar in salivary glands (0. 87 ± 0. 43 Gy/GBq). However, kidneys and red marrow were more exposed to radiation (2. 54 ± 0. 94 Gy/GBq and 0. 29 ± 0. 07 Gy/GBq, respectively)  [104]. Similarly, [ 177 Lu]Lu-EB-PSMA-617 displayed comparable early results and also proved to be effective, with response correlated with treatment dose (up to 2. 12 GBq)  [105] [106] [107]. This radionuclide therapy is currently being investigated in two phase 1 clinical trials involving mCRPC patients (NCT03403595, NCT03780075). Lastly, ibuprofen-containing derivatives such as [ 177 Lu]Lu-Ibu-DAB-PSMA are currently evaluated at the preclinical stage and are characterized by a more favorable safety profile as compared to [ 177 Lu]Lu-PSMA-ALB-56, especially considering hematological toxicity  [108] [109] [110] [111].
To date, numerous phase I/II clinical trials are underway with this radiobioconjugate radiolabeled with 225 Ac (NCT03276572, NCT04506567, NCT04576871, NCT04886986, NCT04946370, NCT05567770)  [115, 116]. Less bulky than monoclonal antibodies, bombesin analog peptides are also interesting vectors for prostate cancer radionuclide therapy as they target a different protein from PSMA, namely the gastrin-releasing peptide receptor (GRPR). For example, [ 177 Lu]Lu-RM2 has been studied in patients with metastatic castration-resistant prostate cancer, showing promising features for clinical use  [117] , and [ 177 Lu]Lu-NeoBOMB1 is currently evaluated in a multicenter clinical trial (NCT03872778) in patients with advanced GRPR-overexpressing solid tumors. A major challenge in the forthcoming years could consist in the efficient management of neuroendocrine-differentiated prostate adenocarcinoma  [118] , most often appearing secondary to treatment with AR inhibitors and displaying decreased or no expression of AR and PSMA  [119].
Abiraterone or United Kingdom enzalutamide United States, Austria, Belgium, Canada, China, France, NCT04689828 - PSMAfore mCRPC [ 177 Lu]Lu-PSMA-617 vs. ARDT 3 Novartis Pharmaceuti-cals Germany, Japan, Netherlands, Poland, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom NCT03315260 - BAYER-19502 mCRPC [ 223 Ra]RaCl 2 4 Bayer Japan NCT04681144 - QOLRAD mCRPC [ 223 Ra]RaCl 2 4 Bayer Colombia 177 Lu/ 225 Ac/ 161 Tb- PSMA ligand, NCT04833517 - REALITY mCRPC or 223 Ra, or [ 153 Sm]Sm-or 90 Y-labeled EDTMP, 4 Universität Saarlandes des Germany microspheres for radioembolization NCT04232761 - RAPIT mCRPC [ 223 Ra]RaCl 2 4 Bayer Taiwan Australia, Austria, Czech Republic, Finland, France, Germany, Hong NCT04597125 - BAYER-20510 mCRPC [ 223 Ra]RaCl 2 vs. 2nd line NAH therapy 4 Bayer Kong, Hungary, Israel, Italy, Korea, Republic of Seoul, Lithuania, Poland, Russian Federation, Singapore, Spain, United Kingdom.
Docetaxel 60 mg/m 2 + 3 Bayer United States, Netherlands [ 223 Ra]RaCl 2 NCT05150236 IO EVOLUTION mCRPC [ 177 Lu]Lu-PSMA-617 vs. [ 177 Lu]Lu-Nivolumab + Ipilimumab + PSMA-617 2 Bristol-Myers Squibb Applications Accelerator Advanced Australia.
Automated reports can be useful to prioritize pathology detection, to help reduce errors and to enrich the radiological report with information that is not usually reported in radiological reports Introduction: ASD corrective surgery involves instrumenting the spine with contoured rods to achieve a correction and modify spinal curvatures. Appropriate rod bending is mandatory to achieve an optimal correction. The relationship between rod and spinal shape has not been reported in long constructs. Materials and Methods: A retrospective review of a prospective multicenter ASD database was performed. Inclusion criteria were all operated patients from the database with pelvic fixation and an upper instrumented vertebra to T12 or above. Patient with multiple rods, connectors and with more than 20 of postoperative coronal cobb angle were excluded.
Materials and Methods: Patients with MESCC diagnosed on MRI between September 2007 and September 2017 were eligible. MRI studies with instrumentation, suboptimal image quality, and non-thoracic regions were excluded. Axial T2-weighted images were utilized and data was obtained using multiple MRI platforms and parameters to prevent overfitting to train a DL model. The internal dataset split was 82% and 18% for training/validation and test sets respectively. External testing was also performed. Internal training/validation data was labelled using the Bilsky MESCC classification by a musculoskeletal radiologist and a neuroradiologist. These labels were used to train a DL model utilizing a prototypical convolutional neural network. Internal and external test sets were labelled by a musculoskeletal radiologist as reference.